Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents

References

• Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol. 2005;45:357–384. DOI:10.1146/annurev.pharmtox.45.120403.100124
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432–1433. DOI:10.1126/science.342.6165.1432
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. DOI:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Khamisipour G, Jadidi N-F, Jahromi AS, et al. Mechanisms of tumour cell resistance to the current-targeted therapy agents. Tumour Biol. 2016;37:10021–10039. DOI: 10.1007/s13277-016-5059-1.
   PubMed Web of Science ®Google Scholar
• Redmond KL, Papafili A, Lawler M, et al. Overcoming resistance to targeted therapies in cancer. Semin Oncol. 2015;42:896–908. DOI:10.1053/j.seminoncol.2015.09.028
   PubMed Web of Science ®Google Scholar
• Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 2015;42:539–548. DOI:10.1053/j.seminoncol.2015.05.015
   PubMed Web of Science ®Google Scholar
• La-Beck NM, Jean GW, Huynh C, et al. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015;35:963–976. DOI:10.1002/phar.1643
   PubMed Web of Science ®Google Scholar
• Robert L, Ribas A, Hu-Lieskovan S. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol. 2016;28:73–80. DOI:10.1016/j.smim.2016.01.001
   PubMed Web of Science ®Google Scholar
• Marrone KA, Ying W, Naidoo J. Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther. 2016;100:242–251. DOI:10.1002/cpt.394
   PubMed Web of Science ®Google Scholar
• Liu S, Kurzrock R. Understanding toxicities of targeted agents: implications for anti-tumour activity and management. Semin Oncol. 2015;42:863–875. DOI:10.1053/j.seminoncol.2015.09.032
   PubMed Web of Science ®Google Scholar
• Enquist E, Zambiano N, Zbar B, et al. Molecular mechanisms of immune dysfunction in renal cell carcinoma. In: Bukowski RM, Novick ACeds. Renal Cell Carcinoma: Molecular Biology, Immunology and Clinical Management. Totowa, NJ: Humana Press; 2000. p. 63–78.
   Google Scholar
• Porta C, Bonomi L, Lillaz B, et al. Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Res. 2007;27:165–173.
   PubMed Web of Science ®Google Scholar
• Hodorová I, Rybárová S, Solár P, et al. Multidrug resistance proteins in renal cell carcinoma. Folia Biol (Praha). 2008;54:187–192.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I, et al. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. Scientific World Journal. 2007;7:837–849. DOI:10.1100/tsw.2007.154
   Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813. DOI:10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunological Rev. 2010;236:219–242. DOI:10.1111/j.1600-065X.2010.00923.x
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann NY Acad Sci. 2011;1217:45–59. DOI:10.1111/j.1749-6632.2010.05919.x
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster anti-tumour immunity. Future Oncol. 2015;11:1307–1326. DOI:10.2217/fon.15.52
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun. 2005;338:627–638. DOI:10.1016/j.bbrc.2005.08.165
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676. DOI:10.1038/nm0603-669
   PubMed Web of Science ®Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(suppl. 3):4–10. DOI:10.1159/000088478
   PubMed Web of Science ®Google Scholar
• Su D, Stamatakis L, Singer EA, et al. Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol. 2014;26:321–327. DOI:10.1097/CCO.0000000000000069
   PubMed Web of Science ®Google Scholar
• Corliss BA, Azimi MS, Munson JM, et al. Macrophages: an inflammatory link between angiogenesis and lymphangiogenesis. Microcirculation. 2016;23:95–121. DOI:10.1111/micc.12259
   PubMed Web of Science ®Google Scholar
• Sorrentino C, Miele L, Porta A, et al. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget. 2015;6:27478–27489. DOI:10.18632/oncotarget.4393
   PubMed Web of Science ®Google Scholar
• Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011;30:83–95. DOI:10.1007/s10555-011-9281-4
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I, et al. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?. J Cancer. 2011;2:333–338.
   PubMed Web of Science ®Google Scholar
• Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007;5:32. DOI:10.1186/1479-5876-5-32
   PubMed Web of Science ®Google Scholar
• Mimura K, Kono K, Takahashi A, et al. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2.. Cancer Immunol Immunother. 2007;56:761–770. DOI:10.1007/s00262-006-0234-7
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl. 3):iii49–iii56. DOI:10.1093/annonc/mdu259
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913–924. DOI:10.1016/j.eururo.2015.01.005
   PubMed Web of Science ®Google Scholar
• Available at: https://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf. Accessed Jun 18, 2016.
   Google Scholar
• Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res. 2007;13:1801–1809. DOI:10.1158/1078-0432.CCR-06-1432
   PubMed Web of Science ®Google Scholar
• Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007;25:3288–3295. DOI:10.1200/JCO.2007.10.8613
   PubMed Web of Science ®Google Scholar
• Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25:3296–3301. DOI:10.1200/JCO.2007.11.1047
   PubMed Web of Science ®Google Scholar
• Jonasch E, Corn P, Pagliaro LC, et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010;116:57–65. DOI:10.1002/cncr.24685
   PubMed Web of Science ®Google Scholar
• Niwakawa M, Hashine K, Yamaguchi R, et al. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. Invest New Drugs. 2012;30:1046–1057. DOI:10.1007/s10637-010-9630-0
   PubMed Web of Science ®Google Scholar
• Huang T, Song XS, Zhang ZW. Efficacies of sorafenib plus interferon in advanced renal cell carcinoma: a report of 57 cases. Zhonghua Yi Xue Za Zhi. 2013;93:1903–1905.
   PubMedGoogle Scholar
• Bracarda S, Porta C, Boni C, et al. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). Eur Urol. 2013;63:254–261. DOI:10.1016/j.eururo.2012.08.027
   PubMed Web of Science ®Google Scholar
• Eto M, Kawano Y, Hirao Y, et al. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan. BMC Cancer. 2015;15:667. DOI:10.1186/s12885-015-1584-3
   PubMed Web of Science ®Google Scholar
• Procopio G, Verzoni E, Bracarda S, et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer. 2011;104:1256–1261. DOI:10.1038/bjc.2011.103
   PubMed Web of Science ®Google Scholar
• Procopio G, Verzoni E, Bracarda S, et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Ann Oncol. 2013;24:2967–2971. DOI:10.1093/annonc/mdt375
   PubMed Web of Science ®Google Scholar
• Monk P, Lam E, Mortazavi A, et al. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. J Immunother. 2014;37:180–186. DOI:10.1097/CJI.0000000000000023
   PubMed Web of Science ®Google Scholar
• Bhatia S, Curti B, Ernstoff MS, et al. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014;2:2. DOI:10.1186/2051-1426-2-2
   PubMedGoogle Scholar
• Motzer RJ, Hudes G, Wilding G, et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009;7:28–33. DOI:10.3816/CGC.2009.n.005
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combined with interferon-alfa for advanced renal cell carcinoma. J Clin Oncol. 2007;25:3958–3964. DOI:10.1200/JCO.2006.10.5916
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281. DOI:10.1056/NEJMoa066838
   PubMed Web of Science ®Google Scholar
• Dutcher JP, De Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26:202–209. DOI:10.1007/s12032-009-9177-0
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–2111. DOI:10.1016/S0140-6736(07)61904-7
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144–2150. DOI:10.1200/JCO.2009.26.7849
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422–5428. DOI:10.1200/JCO.2008.16.9847
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137–2143. DOI:10.1200/JCO.2009.26.5561
   PubMed Web of Science ®Google Scholar
• Negrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011;12:673–680. DOI:10.1016/S1470-2045(11)70124-3
   PubMed Web of Science ®Google Scholar
• Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014;32:752–759. DOI:10.1200/JCO.2013.50.5305
   PubMed Web of Science ®Google Scholar
• Garcia JA, Mekhail T, Elson P, et al. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int. 2011;107:562–570. DOI:10.1111/j.1464-410X.2010.09573.x
   PubMed Web of Science ®Google Scholar
• Dandamudi UB, Ghebremichael M, Sosman JA, et al. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother. 2013;36:490–495. DOI:10.1097/CJI.0000000000000003
   PubMed Web of Science ®Google Scholar
• Buti S, Lazzarelli S, Chiesa MD, et al. Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: an Italian Oncology Group for Clinical Research (GOIRC) study. J Immunother. 2010;33:735–741. DOI:10.1097/CJI.0b013e3181eb8289
   PubMed Web of Science ®Google Scholar
• Donini M, Buti S, Lazzarelli S, et al. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). Target Oncol. 2015;10:277–286. DOI:10.1007/s11523-014-0337-6
   PubMed Web of Science ®Google Scholar
• Amato RJ, Malya R, Rawat A. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. Am J Clin Oncol CCT. 2008;31:237–243. DOI:10.1097/COC.0b013e31815e4505
   PubMed Web of Science ®Google Scholar
• Shek D, Longmate J, Quinn DI, et al. A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. Int J Clin Oncol. 2011;16:494–499. DOI:10.1007/s10147-011-0212-8
   PubMed Web of Science ®Google Scholar
• Amato RJ, Jac J, Hernandez-McClain J. Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. Anticancer Drugs. 2008;19:527–533. DOI:10.1097/CAD.0b013e3282fa4ad2
   PubMed Web of Science ®Google Scholar
• Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014;32(suppl.5): Abstract5010. DOI:10.1200/JCO.2013.54.6911
   PubMed Web of Science ®Google Scholar
• Atkins MB, Gupta S, Choueiri TK, et al. Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma. J Immunother Cancer. 2015;3(suppl. 2):P353. DOI:10.1186/2051-1426-3-S2-P353
   Google Scholar
• Iacovelli R, Nolè F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol. 2016;11:143–148. DOI:10.1007/s11523-015-0392-7
   PubMed Web of Science ®Google Scholar
• Rini BI, Stein M, Shannon P, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011;117:758–767. DOI:10.1002/cncr.25639
   PubMed Web of Science ®Google Scholar
• Figlin RA. Personalised immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma. Expert Opin Biol Ther. 2015;15:1241–1248. DOI:10.1517/14712598.2015.1063610
   PubMed Web of Science ®Google Scholar
• Amin A, Dudek AZ, Logan TF, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy in combination with sunitinib in unfavourable risk patients with advanced renal cell carcinoma (RCC): phase 2 study result. J Immunother Cancer. 2015;3:14. DOI:10.1186/s40425-015-0055-3
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18:1254–1261. DOI:10.1038/nm.2883
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14:6674–6682. DOI:10.1158/1078-0432.CCR-07-5212
   PubMed Web of Science ®Google Scholar
• Rini B, Stenzl A, Zdrojowy R, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1599–1611. DOI:10.1016/S1470-2045(16)30408-9
   PubMed Web of Science ®Google Scholar
• Nadal R, Amin A, Geynisman DM, et al. Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol. 2015;33(suppl.); Abstract 4566.
   Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920. DOI:10.1016/S0140-6736(16)00561-4
   PubMed Web of Science ®Google Scholar
• Sznol M, McDermott DF, Fields Jones S, et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2015;33(suppl.); Abstract 410.
   Google Scholar
• Powles T, Bracarda S, Chen M, et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer. 2015;51:1293–1302. DOI:10.1016/j.ejca.2015.03.019
   PubMed Web of Science ®Google Scholar